Medicine composition of imipenem-cilastatin-tazobactam

A technology of imipenem and cilastatin sodium, which is applied to the combined drug of imipenem and cilastatin sodium/tazobactam sodium, and the field of combined drug, can solve the problem of multi-drug resistant Bowman's immobility. Bacillus invasion and other issues

Active Publication Date: 2012-12-05
深圳麦德凯诺医药科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Carbapenems are the drug of choice for the treatment of severe Acinetobacter baumannii infections, but carbapenem-multidrug-resistant strains have emerged around the world in recent years, with worrying multi-drug resistance emerging from Spain to Norway The "invasion" phenomenon of Acinetobacter baumannii is prevalent among traumatized soldiers of the U.S. and British troops stationed in Afghanistan and Iraq, causing serious public health problems. Acinetobacter baumannii brought back by the U.S. military in Iraq is prevalent in the United States

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition of imipenem-cilastatin-tazobactam
  • Medicine composition of imipenem-cilastatin-tazobactam
  • Medicine composition of imipenem-cilastatin-tazobactam

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Study on antibacterial effect of imipenem cilastatin sodium / tazobactam sodium in vitro

[0034] 1. Test drugs:

[0035] Imipenem, imipenem cilastatin sodium, and tazobactam sodium were purchased from China Institute for the Control of Pharmaceutical and Biological Products.

[0036] The following proportions are calculated by weight, wherein the weight of imipenem and imipenem cilastatin sodium is calculated by the dry conversion of imipenem, and the weight of tazobactam sodium is calculated by the dry conversion of tazobactam sodium Calculated by tazobactam.

[0037] 2. Test ratio:

[0038] (1) Imipenem

[0039] (2) Tazobactam sodium

[0040] (3) Imipenem cilastatin sodium / tazobactam sodium (2:1)

[0041] (4) Imipenem cilastatin sodium / tazobactam sodium (1:1)

[0042] (5) Imipenem cilastatin sodium / tazobactam sodium (1:2)

[0043] (6) Imipenem cilastatin sodium / tazobactam sodium (1:4)

[0044] 3. Test strains:

[0045] In this experiment, 89 imipene...

Embodiment 2

[0075] Example 2: Study on the antibacterial effect of imipenem cilastatin sodium / tazobactam sodium in vivo

[0076] 1. In vivo antibacterial effect study of single dose of imipenem cilastatin sodium and different formulations of imipenem cilastatin sodium / tazobactam sodium

[0077] Combination drug of imipenem cilastatin sodium and tazobactam sodium in weight ratio (2:1), (1:1), (1:2), (1:4), (1:9) , had a significant antibacterial therapeutic effect on infected mice.

[0078] 1 Test drug

[0079] Imipenem, imipenem cilastatin sodium, and tazobactam sodium were purchased from China Institute for the Control of Pharmaceutical and Biological Products.

[0080] Small white mice, Kunming species, weighing 18-22g, half male and half male. Provided by the Experimental Animal Laboratory of the Second Hospital of China Medical University. Certificate number, Liao Shi Dong Gong Zi 031. Randomly divided into groups, 10 in each group, half male and half male. Set up 6 dose groups,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a combination medicine, and specifically provides a combination medicine of imipenem-cilastatin-tazobactam for treating infectious diseases caused by acinetobacter baumanii. The combination medicine of imipenem-cilastatin-tazobactam has synergistic and accumulated antibacterial effects on the infectious diseases caused by acinetobacter baumanii, particularly has excellent synergistic and accumulated antibacterial effects on a multidrug-resistant acinetobacter baumanii strain, and also can be used for curing clinical infection caused by the multidrug-resistant acinetobacter baumanii.

Description

technical field [0001] The invention provides a combination medicine, in particular, a combination medicine of imipenem cilastatin sodium / tazobactam sodium for treating infectious diseases caused by Acinetobacter baumannii. It belongs to the field of medical technology. Background technique [0002] Carbapenem antibiotics are a class of antibiotics with the broadest antibacterial spectrum and strong antibacterial activity so far. In the past 20 years, imipenem and cilastatin sodium among carbapenems have been used as compound preparations. Its components are imipenem 500mg and cilastatin sodium (calculated as C16H25N2O5S) 500mg, which are key drugs for the treatment of severe infections, especially in the treatment of severe infections of the respiratory tract, which have irreplaceable curative effects and have saved the lives of countless patients , but with the widespread use of carbapenems, the resistance rate of Acinetobacter baumannii to carbapenems has increased year ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/431A61K31/407A61K31/198A61P31/04
Inventor 邱初
Owner 深圳麦德凯诺医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap